{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:56:37Z","timestamp":1784123797390,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P400PM_191032"],"award-info":[{"award-number":["P400PM_191032"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["16.921318"],"award-info":[{"award-number":["16.921318"]}],"id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.euroneuro.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T18:20:54Z","timestamp":1648837254000},"page":"9-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: ,\u03b1-DEPEA and DPIA"],"prefix":"10.1016","volume":"59","author":[{"given":"Karolina E.","family":"Kolaczynska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4690-4051","authenticated-orcid":false,"given":"Paula","family":"Ducret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Trachsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-6250","authenticated-orcid":false,"given":"Marius C.","family":"Hoener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-4875","authenticated-orcid":false,"given":"Dino","family":"Luethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.euroneuro.2022.03.006_bib0001","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.284.17.2190","article-title":"Chemical analysis of ecstasy pills","volume":"284","author":"Baggott","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.006_bib0002","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/02791072.2019.1593560","article-title":"Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers","volume":"51","author":"Baggott","year":"2019","journal-title":"J. Psychoactive Drugs"},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.006_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0026-895X(25)09398-8","article-title":"Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter","volume":"50","author":"Barker","year":"1996","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0004","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.110.176271","article-title":"In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat","volume":"337","author":"Baumann","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.006_bib0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-006-0322-6","article-title":"3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings","volume":"189","author":"Baumann","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2022.03.006_bib0006","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0379-0738(01)00548-5","article-title":"\u03b1-Phenylethylamine in illegally produced amphetamine","volume":"123","author":"Blachut","year":"2001","journal-title":"Forensic Sci. Int."},{"issue":"5","key":"10.1016\/j.euroneuro.2022.03.006_bib0007","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"ChemBioChem"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2022.03.006_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0091-3057(95)00013-M","article-title":"A behavioral comparison of Nexus, cathinone, BDB, and MDA","volume":"51","author":"Bronson","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2022.03.006_bib0009","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0091-3057(95)00012-L","article-title":"Structure-activity relationships of BDB and its monomethyl and dimethyl derivatives","volume":"51","author":"Bronson","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0028-3908(95)00134-4","article-title":"[3H]Nisoxetine\u2014A radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments","volume":"35","author":"Cheetham","year":"1996","journal-title":"Neuropharmacology"},{"issue":"7\u20138","key":"10.1016\/j.euroneuro.2022.03.006_bib0011","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/dta.1578","article-title":"A methamphetamine analog (N,\u03b1-diethyl-phenylethylamine) identified in a mainstream dietary supplement","volume":"6","author":"Cohen","year":"2014","journal-title":"Drug Test Anal."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0012","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-3565(25)39080-4","article-title":"Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine","volume":"242","author":"D'Amato","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.006_bib0013","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition","volume":"26","author":"de la Torre","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fgene.2012.00235","article-title":"MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?","volume":"3","author":"de la Torre","year":"2012","journal-title":"Front Genet."},{"issue":"47","key":"10.1016\/j.euroneuro.2022.03.006_bib0015","doi-asserted-by":"crossref","first-page":"16928","DOI":"10.1523\/JNEUROSCI.2502-11.2011","article-title":"Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA)","volume":"31","author":"Di Cara","year":"2011","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00005053-195808000-00011","article-title":"Preliminary study of a new anti-depressant drug","volume":"127","author":"Friedhoff","year":"1958","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0018","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.physbeh.2018.12.007","article-title":"3,4-Methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats","volume":"199","author":"Hake","year":"2019","journal-title":"Physiol. Behav."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0019","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1520\/JFS11822J","article-title":"Di-(\u03b2-phenylisopropyl)amine in illict amphetamine","volume":"30","author":"Huizer","year":"1985","journal-title":"J. Forensic Sci."},{"issue":"8","key":"10.1016\/j.euroneuro.2022.03.006_bib0021","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1476-5381.2012.01936.x","article-title":"Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans","volume":"166","author":"Hysek","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2022.03.006_bib0022","doi-asserted-by":"crossref","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","article-title":"Duloxetine inhibits effects of MDMA (\"ecstasy\") in vitro and in humans in a randomized placebo-controlled laboratory study","volume":"7","author":"Hysek","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0023","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3389\/fphar.2020.00673","article-title":"Cell-based radiotracer binding and uptake inhibition assays: a comparison of in vitro methods to assess the potency of drugs that target monoamine transporters","volume":"11","author":"Ilic","year":"2020","journal-title":"Front Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0026-895X(25)14974-2","article-title":"[3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites","volume":"26","author":"Javitch","year":"1984","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.euroneuro.2022.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1360-0443.2007.01874.x","article-title":"Methamphetamine and cardiovascular pathology: a review of the evidence","volume":"102","author":"Kaye","year":"2007","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.03.006_bib0026","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0306-3623(90)91034-O","article-title":"Pharmacologic and toxicologic effects of di(\u03b2-phenylisopropyl)amine (DPIA) in rats and mice","volume":"21","author":"Ketema","year":"1990","journal-title":"Gen. Pharmacol."},{"issue":"7\u20138","key":"10.1016\/j.euroneuro.2022.03.006_bib0027","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/dta.1570","article-title":"New phenethylamines in Europe","volume":"6","author":"King","year":"2014","journal-title":"Drug Test Anal."},{"issue":"12","key":"10.1016\/j.euroneuro.2022.03.006_bib0028","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0006-2952(00)00284-7","article-title":"Identification of the human cytochromes P450 involved in the oxidative metabolism of \"ecstasy\"-related designer drugs","volume":"59","author":"Kreth","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.006_bib0029","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jat\/20.6.512","article-title":"Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users","volume":"20","author":"Kronstrand","year":"1996","journal-title":"J. Anal. Toxicol."},{"issue":"4474","key":"10.1016\/j.euroneuro.2022.03.006_bib0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1126\/science.7444441","article-title":"High-Affinity [3H]Imipramine Binding in Rat Hypothalamus: association with Uptake of Serotonin But Not of Norepinephrine","volume":"210","author":"Langer","year":"1980","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.euroneuro.2022.03.006_bib0031","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1523\/JNEUROSCI.02-10-01515.1982","article-title":"Characterization of [3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes","volume":"2","author":"Lee","year":"1982","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0032","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11419-013-0205-6","article-title":"Identification and quantitation of N,\u03b1-diethylphenethylamine in preworkout supplements sold via the Internet","volume":"32","author":"Lee","year":"2014","journal-title":"Forensic Toxicol."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0033","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0034","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1520\/JFS10529J","article-title":"Contaminants in illict amphetamine preparations","volume":"21","author":"Lomonte","year":"1976","journal-title":"J. Forensic Sci."},{"issue":"Pt A","key":"10.1016\/j.euroneuro.2022.03.006_bib0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuropharm.2017.08.020","article-title":"Pharmacological profile of methylphenidate-based designer drugs","author":"Luethi","year":"2018","journal-title":"Neuropharmacology 134"},{"issue":"Pt A","key":"10.1016\/j.euroneuro.2022.03.006_bib0036","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2017.07.026","article-title":"Pharmacological profile of mephedrone analogs and related new psychoactive substances","author":"Luethi","year":"2018","journal-title":"Neuropharmacology 134"},{"issue":"7","key":"10.1016\/j.euroneuro.2022.03.006_bib0037","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0269881119844185","article-title":"Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems","volume":"33","author":"Luethi","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2022.03.006_bib0038","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ijnp\/pyy047","article-title":"Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics","volume":"21","author":"Luethi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.006_bib0039","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0040","series-title":"5-HT2B Receptors: From Molecular Biology to Clinical Applications","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-030-55920-5_16","article-title":"Drugs of Abuse Affecting 5-HT2B Receptors","author":"Luethi","year":"2021"},{"issue":"Pt A","key":"10.1016\/j.euroneuro.2022.03.006_bib0041","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2017.07.012","article-title":"Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)","volume":"134","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.euroneuro.2022.03.006_bib0042","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.euroneuro.2022.03.006_bib0043","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1124\/dmd.108.021543","article-title":"The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers","volume":"36","author":"Meyer","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.006_bib0044","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.euroneuro.2022.03.006_bib0045","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"10.1016\/j.euroneuro.2022.03.006_bib0046","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.bjp.0707473","article-title":"Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines","volume":"152","author":"Montgomery","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0047","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pneurobio.2007.01.001","article-title":"Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors","volume":"81","author":"Muller","year":"2007","journal-title":"Prog. Neurobiol."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2022.03.006_bib0048","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2006.11.075","article-title":"The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain","volume":"559","author":"Nagai","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.006_bib0049","first-page":"359","article-title":"Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy","volume":"17","author":"Naranjo","year":"1967","journal-title":"Med. Pharmacol. Exp. Int. J. Exp. Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.006_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens","volume":"18","author":"Nichols","year":"1986","journal-title":"J. Psychoactive Drugs"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.006_bib0051","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0052","first-page":"331","article-title":"Identification of di(\u03b2-phenylisopropyl)amine as the main ingredient in illicit amphetamine tablets","volume":"38","author":"Ottaviano","year":"2002","journal-title":"Ann. Ist. Super Sanita"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0053","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0054","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneumeth.2004.09.015","article-title":"Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity","volume":"143","author":"Reith","year":"2005","journal-title":"J. Neurosci. Methods"},{"issue":"12","key":"10.1016\/j.euroneuro.2022.03.006_bib0055","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/npp.2012.109","article-title":"Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine","volume":"37","author":"Revel","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"10.1016\/j.euroneuro.2022.03.006_bib0056","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0057","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euroneuro.2014.12.012","article-title":"Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones","volume":"25","author":"Rickli","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"13","key":"10.1016\/j.euroneuro.2022.03.006_bib0058","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1111\/bph.13128","article-title":"Pharmacological profile of novel psychoactive benzofurans","volume":"172","author":"Rickli","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0059","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2003.08.054","article-title":"Monoamine transporters and psychostimulant drugs","volume":"479","author":"Rothman","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1196\/annals.1369.064","article-title":"Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs","volume":"1074","author":"Rothman","year":"2006","journal-title":"Ann. N Y Acad. Sci."},{"issue":"23","key":"10.1016\/j.euroneuro.2022.03.006_bib0061","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.euroneuro.2022.03.006_bib0062","doi-asserted-by":"crossref","first-page":"PL267","DOI":"10.1016\/0024-3205(93)90602-Y","article-title":"Studies of the biogenic amine transporters. II. A brief study on the use of [3H] DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists","volume":"53","author":"Rothman","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113778","article-title":"Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics","volume":"343","author":"Rudin","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0064","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41386-021-01221-0","article-title":"(2-Aminopropyl)benzo[\u03b2]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice","volume":"47","author":"Rudin","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/mol.115.101394","article-title":"Binding mode selection determines the action of ecstasy homologs at monoamine transporters","volume":"89","author":"Sandtner","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0066","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bph.12423","article-title":"Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats","volume":"171","author":"Schindler","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0067","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00501873","article-title":"Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease","volume":"329","author":"Schoemaker","year":"1985","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0068","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0022-3565(24)39309-7","article-title":"Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter","volume":"293","author":"Scholze","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.006_bib0069","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200544060-00006","article-title":"Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe","volume":"44","author":"Segura","year":"2005","journal-title":"Clin. Pharmacokinet"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.14219\/jada.archive.2010.0165","article-title":"The relationship between methamphetamine use and increased dental disease","volume":"141","author":"Shetty","year":"2010","journal-title":"J. Am. Dent. Assoc."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0071","series-title":"PiHKAL: A Chemical Love Story","author":"Shulgin","year":"1991"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0072","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.115.229765","article-title":"In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1","volume":"357","author":"Simmler","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.006_bib0073","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.006_bib0074","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","article-title":"Amphetamines, new psychoactive drugs and the monoamine transporter cycle","volume":"36","author":"Sitte","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0075","series-title":"Report on clinical evaluation of SKF #5 (Amphedoxamine)","author":"Smith Kline","year":"1957"},{"issue":"7\u20138","key":"10.1016\/j.euroneuro.2022.03.006_bib0076","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/dta.413","article-title":"Fluorine in psychedelic phenethylamines","volume":"4","author":"Trachsel","year":"2012","journal-title":"Drug Test Anal."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0077","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cbdv.200690035","article-title":"Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and its derivatives","volume":"3","author":"Trachsel","year":"2006","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0078","series-title":"Phenethylamine: Von der Struktur zur Funktion","author":"Trachsel","year":"2013"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.006_bib0079","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/jat\/bkt121","article-title":"Designer phenethylamines routinely found in human urine: 2-ethylamino-1-phenylbutane and 2-amino-1-phenylbutane","volume":"38","author":"Uralets","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0080","first-page":"902","article-title":"Phenylisopropylamine derivatives, structure and action","volume":"12","author":"van der Schoot","year":"1962","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.006_bib0081","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.108.136200","article-title":"Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition","volume":"325","author":"Walline","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2022.03.006_bib0082","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jpba.2015.07.025","article-title":"Determination of designer doping agent\u20132-ethylamino-1-phenylbutane \u2013 in dietary supplements and excretion study following single oral supplement dose","volume":"115","author":"Wojtowicz","year":"2015","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:02:01Z","timestamp":1760378521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":82,"alternative-id":["S0924977X22001560"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: N,\u03b1-DEPEA and DPIA","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}